<DOC>
	<DOCNO>NCT01841489</DOCNO>
	<brief_summary>This Phase 1 , Open-Label , Adaptive Study Novel GS-9973 Tablet Formulations Evaluate Effect Acid Reducing Agents , Relative Bioavailability , Food Effect GS-9973 Pharmacokinetics .</brief_summary>
	<brief_title>A Phase 1 Study Novel GS-9973 Tablet Formulations Evaluate Effect Acid Reducing Agents , Relative Bioavailability , Food Effect GS-9973 Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Have ability understand sign write informed consent form , must obtain prior initiation study procedure Must body mass index ( BMI ) range approximately 19 30 kg/m2 Must minimum weight 45 kg Females childbearing potential must negative serum pregnancy test screen baseline must practice least 1 reliable method contraception define protocol Female subject utilize hormonal contraceptive 1 birth control method must use method least 3 month prior study dose Male subject must agree use condom heterosexual intercourse avoid sperm donation Day 1 90 day follow last dose study medication Must refrain blood donation throughout study period Must , opinion Investigator , good general Must non light smoker , eg , less 10 cigarette per day Pregnant lactating subject Use prescribe overthecounter medication affect gastric pH History severe peptic ulcer disease , GERD , diseases require prolong ( &gt; 6 week ) medication surgical therapy modify gastric pH Have history clinically significant cardiac abnormality presence clinically significant abnormality 12lead ECG . Have history cancer require systemic chemotherapy radiation Have history bleeding disorder Have history liver disorder Current acute infection history acute infection within 7 day Have recent history alcohol illicit drug abuse and/or positive test select drug abuse Have positive hepatitis screen positive Human Immunodeficiency Virus antibody test Have participate another clinical trial within 28 day Have receive transfusion blood plasma product within 6 month Have donate &gt; 500 mL blood within 56 day Are unable unwilling comply study restriction , return followup appointment , consideration , opinion Investigator , would make candidate unsuitable study participation Current historical medical condition deem medical significance Investigator Have use prescription medication , counter product , herbal remedy nutritional supplement within 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>